Researchers have analysed the therapeutic benefits of an antiviral drug, nirmatrelvir, and a class of drugs typically used for bone disorders, bisphosphonates, on the coronavirus. Nirmatrelvir treatment proved effective in preventing severe disease but might impact the host immune system’s ability to combat the virus in future. Meanwhile, bisphosphonates were found to enhance antibody responses to viral antigens, reducing COVID-19 risk and hospitalisation rates.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
